NIVS System Update 27th May 2021

Dear Colleagues

In response to a rapid development requirement from the national programme, we have made some changes to the Pre-Screening data collection page, as well as some refinements from user feedback. These changes have been pushed through at pace hence the late communication.

Pre Screening

Two additional questions are now required to be completed at the start of prescreening:

- Planned Vaccine to be given
- First Dose (Y/N)

Depending upon the combination of these selections, you will be asked to complete additional pre screening questions.

anned Vaccine Type			First Dose?		
AstraZeneca 0.5ml dose		~	✓ O Yes O No		
e-screening Captured Elsewhere?	Date	Prescreening Clinician		Bookin	g Number
Yes 🔍 No	12/05/2021	iii ii			
ease ask the individual province of the purport of	ose of the vaccine and	tion these questions and rec d side effects.	ord that they have re		appropria ○ _{No}
Are you currently unwell wit	:h fever?			○ Yes	○ No
• Have you ever had any serio See later for link to ingredient	5	/ ingredients of the Covid-19 vaccine	es, drug or other vaccine?*	○ Yes	○ No
Have you ever had an unexp	plained anaphylaxis reaction	on?*		○ Yes	○ No
• Do you have a history of he	parin-induced thrombocyt	topenia and thrombosis (HITT or HI	T type 2)?	○ Yes	○ No
		nrombosis occurring with thromboc	ytopenia following	○ Yes	○ No
 Have you experienced majo vaccination with any COVID 	-19 vaccine?				
				○ Yes	○ No
vaccination with any COVID	egnant?	navirus vaccine?#			○ No ○ No
vaccination with any COVIDAre you, or could you be presented and the presented of the prese	egnant? a a trial of a potential corol			⊖ Yes	

If you or the person presenting for vaccination are uncertain as to the response made for any of the questions or the counselling they should receive, they should be referred or brought to the attention of the clinical supervisor/lead clinician as required for further advice.

Cautions - to have clinical evaluation prior to vaccination in accordance with Immunisation against Infectious Diseases (the Green Book).

Please click here for specific advice on management of the cautions listed above.

If Planned Vaccine Type is AstraZeneca and First Dose is No then a new question need to be completed:

• Has [the patient] experienced an urticarial skin reaction following a COVID-19 vaccine?

Planned Vaccine Type			First Dose?
AstraZeneca 0.5ml dose		~	○ Yes ● No
Have you experienced an urticarial (itcl	ny) skin reaction following a C	COVID-19 vaccine?	
⊖ Yes ⊖ No			
Pre-screening Captured Elsewhere?	Date	Prescreening Clinician	Booking Number
○ Yes ● No	12/05/2021		
AstraZeneca 0.5ml dose		~	○ Yes ● No
Planned Vaccine Type			First Dose?
Have you experienced an urticarial (itch	ny) skin reaction following a C	COVID-19 vaccine?	
● Yes ○ No			
If the patient's first dose was a mandatory 30 mins obs		nen the patient can be considered for ha	ving the AstraZeneca vaccine provided there
If the patient's first dose w with full resuscitation faci		ot Pfizer or Moderna), then the patient s	hould ONLY have the second dose in a place
Pre-screening Captured Elsewhere?	Date	Prescreening Clinician	Booking Number
○ Yes	12/05/2021	i	

These follow the guidelines from the National Program for pre-screening requirements.

Some additional changes to the look of the pre-screening have also been implemented. Clicking yes on any of the existing pre-screening questions will also flag alerts to the user:

Please ask the individual presenting for vaccination these questions and record that they have received appropriate counselling as to the purpose of the vaccine and side effects.

•	Have you had any vaccination in the last 7 days?	Yes	⊖ No	
•	Are you currently unwell with fever?	Yes	○ No	
•	Have you ever had any serious allergic reaction to any ingredients of the Covid-19 vaccines, drug or other vaccine?* See later for link to ingredients list.	Yes	⊖ No	
•	Have you ever had an unexplained anaphylaxis reaction?*	Yes	○ No	
•	Do you have a history of heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2)?	Yes	○ No	
	A further clinical review must take place!			
•	Are you, or could you be pregnant?	Yes	○ No	
•	Are you or have you been in a trial of a potential coronavirus vaccine?#	Yes	○ No	
•	Are you taking anticoagulant medication, or do you have a bleeding disorder?	Yes	○ No	
•	Do you currently have any symptoms of COVID-19 infection?**	Yes	○ No	
	A clinical evaluation prior to vaccination is required!			
•	and the end of the second s	10 - 10		••

Finally, a comments box for recording any decisions or observations is now available and there is a declaration to be recorded that the patient is clinically suitable for the vaccination:

		made for any of the questions or the counselling they should rvisor/lead clinician as required for further advice.				
Cautions – to have clinical evaluation prior to vaccination in accordance with Immunisation against Infectious Diseases (the Green Book).						
Please click here for specific a	dvice on management of the cautions listed abov	e.				
Comment						
Consented For Vaccination?	Consent Type					
● Yes ○ No	Please Select	~				
Clinically Suitable?	Pre-screening Outcome					
⊖Yes ⊖No	Please Select	~				
	-					
		B Save				

VACCINATION AGE WARNINGS

In addition, further validation warnings are in place. If a patient is under 40, then a warning will appear where the patient is offered the AstraZeneca Vaccine:

AZ43273 AstraZ Vaccine Type AstraZeneca 0.5ml dose	eneca v 13/09/2021 Vaccination Site Dose	
	Vaccination Site Dose	
AstraZeneca 0.5ml dose		
	✓ Left Thigh ✓ Administration	on of first dose of SARS-CoV-2 🗸 🗸
You have selected the AstraZeneca vaccine for a per the age of 40. Pfizer and Moderna vaccines are pre recommended by JCVI. Please discuss the appropri vaccination with AstraZeneca with the clinical lead vaccination site.	ferred as iateness of at the	
Vaccinator Organisation Essex University Partnership Trust (EPUT)	Vaccination Geo Site	~

This warning will also appear on the prescreening page for the first dose, where the Planned Vaccine Type is AstraZeneca, and the patient is under 40 years of age:

anned Vaccine Type				First Dose?	
AstraZeneca 0.5ml dose			~	● Yes ○ No	
You have selected the AstraZeneca vaccine for a person under the age of 40. Pfizer and Moderna vaccines are preferred as recommended by JCVI. Please discuss the appropriateness of vaccination with AstraZeneca with the clinical lead at the vaccination site.					
re-screening Captured Elsewhere?	Date	Prescreening Clinicia	ı		Booking Number
) Yes 💿 No	dd/mm/yyyyy				

SIDE EFFECTS GUIDANCE

There is now a question at the bottom of the Add Vaccination screen to prompt the vaccinator to supply the appropriate post-vaccination material with a link to the Government website for further information:

🖬 Save

Has the patient received all the relevant post-vaccination information? (Further guidance on what to expect after a vaccination can be found here.)
● Yes ○ No

IMMUNISATION STATUS SEARCH

A Clear Search button has been added to the Immunisation Status screen to allow the user to remove any current demographics within the search fields:

Immunisatic	on Status Search				•
NHS Number		Q			Clear Search
Forename	Surname	Date Of Birth	Gender	Postcode	
		dd/mm/yyyy	🗎 Please Selec		Q

PERTIAL POSTCODE SEARCH

You can now search using a partial postcode on the Patient Search screen:

2 Patient Search							
NHS Number	Forename	Surname			Postcode		
			d	d/mm/yyyy 🛗	CV33 Q Search		
Patients					+ New Patient		
NHS N	umber	Name	Date Of Birth	Postco	ode Edit		
99999	99999	Harri Chapman	28/05/1984	CV33 9	ərz 🗹		

NHS NUMBER SEARCH

The system will now allow users to paste in an NHS Number with spaces (e.g. 111 111 1111) into the NHS Number boxes. NIVS will automatically remove the spaces and allow the search to be performed.